BenzingaThu, 12 Mar 2026 11:47:47 GMTBridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early ProgressBBIO+1.35%
Seeking AlphaWed, 11 Mar 2026 19:02:22 GMTBridgeBio Pharma, Inc. (BBIO) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptBBIO+1.35%
Investors Business DailyTue, 10 Mar 2026 18:34:11 GMTWhy BridgeBio Leapfrogged Its 50-Day Line On Pfizer's Patent Shake-UpBBIO+1.35%
Zacks Investment ResearchWed, 25 Feb 2026 01:31:57 GMTBridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue EstimatesBBIO+1.35%
Seeking AlphaWed, 25 Feb 2026 00:27:51 GMTBridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call TranscriptBBIO+1.35%
Seeking AlphaThu, 12 Feb 2026 22:54:19 GMTBridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia TranscriptBBIO+1.35%
Zacks Investment ResearchThu, 12 Feb 2026 16:05:50 GMTBridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseBBIO+1.35%
Investors Business DailyThu, 12 Feb 2026 12:30:23 GMTBridgeBio Unveils Positive Results For Its Most 'Hotly Debated' Phase 3 DrugBBIO+1.35%
Zacks Investment ResearchMon, 09 Feb 2026 09:30:22 GMTBridgeBio Pharma (BBIO) Surges 6.8%: Is This an Indication of Further Gains?BBIO+1.35%
Seeking AlphaMon, 09 Feb 2026 06:10:13 GMTBridgeBio: Initiating At A Neutral Rating, Stock Priced At PerfectionBBIO+1.35%
